

# Contents

## CHAPTER 1

### Introduction

J.W. FISHER. . . . .	1
----------------------	---

## CHAPTER 2

### Fundamental Control of Hematopoiesis

C.J. EAVES and A.C. EAVES. With 4 Figures . . . . .	5
A. Introduction . . . . .	5
B. Hierarchical Organization of Hematopoietic Cells . . . . .	9
C. Assay and Characterization of In Vitro Clonogenic Cells . . . . .	12
D. Use of In Vitro Clonogenic Cell Assays . . . . .	17
E. Newer Assays for More Primitive Cells . . . . .	20
F. Regulatory Mechanisms . . . . .	23
G. Future Outlook . . . . .	24
References . . . . .	25

## CHAPTER 3

### Kidney Regulation of Erythropoietin Production

J.W. FISHER and J. NAKASHIMA. With 13 Figures . . . . .	33
A. Introduction . . . . .	33
B. Model for the Control of Erythropoietin Production . . . . .	33
C. Hypoxia and Erythropoietin Production . . . . .	36
D. Adenosine and Erythropoietin Production . . . . .	40
References . . . . .	46

## CHAPTER 4

**The Mechanism of Action of Erythropoietin: Erythroid Cell Response**

J.L. SPIVAK. With 2 Figures . . . . .	49
A. Introduction . . . . .	49
I. The Erythropoietin Gene . . . . .	50
II. The Erythropoietin Molecule . . . . .	51
III. Erythropoietin-Responsive Cells . . . . .	55
IV. The Erythroid Burst-Forming Unit . . . . .	58
V. The Colony-Forming Unit Erythroid . . . . .	59
B. Model Systems for Studying the Interaction of Erythropoietin with Erythroid Progenitor Cells. . . . .	60
I. The Erythropoietin Receptor . . . . .	64
C. Interaction of Other Growth and Development Factors with Erythroid Progenitor Cells . . . . .	74
D. The Erythroid Differentiation Program . . . . .	79
I. Gene Expression During Erythroid Cell Differentiation . . . . .	80
E. Signal Transduction in Erythroid Progenitor Cells . . . . .	84
F. Erythropoietin as a Competence or Progression Factor . . . . .	90
G. Conclusion . . . . .	93
References . . . . .	94

## CHAPTER 5

**The Arachidonic Acid Cascade and Erythropoiesis**

B.S. BECKMAN and M. MASON-GARCIA. With 8 Figures . . . . .	115
A. Introduction . . . . .	115
I. Background . . . . .	115
II. Classification of Eicosanoids and Their Chemistry . . . . .	117
1. Prostaglandins. . . . .	117
2. Thromboxanes . . . . .	118
3. Hydroperoxy/Hydroxy Fatty Acids . . . . .	118
4. Leukotrienes . . . . .	119
5. Diglyceride, Phosphatidic Acid, and Lysophosphatidic Acid . . . . .	119
III. Erythropoiesis and Eicosanoids. . . . .	120
B. Evidence for the Roles of Arachidonic Acid Metabolism in Erythropoiesis . . . . .	120
I. Criteria for Implicating Eicosanoids . . . . .	120
II. Target Cell Responses . . . . .	122
III. Cell-Cell Interactions . . . . .	125
IV. Specific Involvement of the Lipoxygenase Pathway . . . . .	126
C. Future Directions for Research . . . . .	129
References . . . . .	130

## CHAPTER 6

**Iron Deficiency and Megaloblastic Anemias**

L.R. SOLOMON. With 6 Figures . . . . .	137
A. Iron-Deficiency Anemia . . . . .	137
I. Introduction . . . . .	137
II. Iron Metabolism . . . . .	137
1. Iron Absorption . . . . .	138
a) Nonheme Iron Absorption . . . . .	139
b) Heme Iron Absorption . . . . .	142
c) Regulation of Iron Absorption . . . . .	143
2. Iron Transport . . . . .	145
3. Intracellular Iron Metabolism . . . . .	148
4. Iron Storage . . . . .	148
III. Biochemical and Physiologic Roles of Iron in Mammalian Tissues . . . . .	149
IV. Iron-Deficiency Anemia . . . . .	150
1. Clinical Aspects . . . . .	150
2. Diagnosis of Iron Deficiency . . . . .	151
3. Management of Iron Deficiency . . . . .	154
a) Oral Iron Therapy . . . . .	155
b) Parenteral Iron Therapy . . . . .	155
B. Megaloblastic Anemias . . . . .	157
I. Definition and Differential Diagnosis . . . . .	157
II. Clinical Manifestations . . . . .	158
III. Biochemistry of Folic Acid and Vitamin B <sub>12</sub> . . . . .	159
IV. Vitamin B <sub>12</sub> Deficiency . . . . .	164
1. General Considerations . . . . .	164
2. Vitamin B <sub>12</sub> Metabolism . . . . .	164
a) Vitamin B <sub>12</sub> Binding Proteins . . . . .	164
b) Vitamin B <sub>12</sub> Absorption . . . . .	167
c) Transport and Intracellular Metabolism of Vitamin B <sub>12</sub> . . . . .	169
3. Causes of Vitamin B <sub>12</sub> Deficiency . . . . .	169
4. Diagnosis of Vitamin B <sub>12</sub> Deficiency . . . . .	171
5. Management of Vitamin B <sub>12</sub> Deficiency . . . . .	173
V. Folate Deficiency . . . . .	174
1. General Considerations . . . . .	174
2. Folate Metabolism . . . . .	176
a) Folate Absorption . . . . .	176
b) Transport and Intracellular Metabolism of Folate . . . . .	178
3. Causes of Folate Deficiency . . . . .	179
4. Diagnosis of Folate Deficiency . . . . .	181
5. Management of Folate Deficiency . . . . .	182
References . . . . .	183

## CHAPTER 7

**Erythropoietin in the Anemia of End-Stage Renal Disease**

R.D. LANGE. With 3 Figures . . . . .	223
A. Assay of Erythropoietin . . . . .	223
B. Pathogenesis of the Anemia of Chronic Renal Failure . . . . .	225
I. Inhibition of Erythropoietin Action . . . . .	230
II. Inhibition of Heme Synthesis . . . . .	231
III. Inhibition of Colony Formation . . . . .	231
C. Kidney Production of Erythropoietin . . . . .	238
D. Erythropoietin in Therapy of Renal Anemia . . . . .	244
E. Conclusions . . . . .	248
References . . . . .	249

## CHAPTER 8

**Humoral Control of Thrombocytopoiesis**

T.P. McDONALD. With 1 Figure . . . . .	267
A. Introduction . . . . .	267
B. Model for Megakaryocytopoiesis . . . . .	267
C. Controlling Factors . . . . .	268
I. Megakaryocyte-Colony Stimulating Factor . . . . .	268
II. Autoregulation of Megakaryocytopoiesis . . . . .	269
III. Thrombopoietin . . . . .	270
1. Background and Historical Aspects . . . . .	270
2. Assays . . . . .	271
3. Site of Production . . . . .	272
4. Antibodies to Thrombopoietin . . . . .	274
5. Purification . . . . .	275
a) Methods for Purification . . . . .	275
b) Characterization of the Molecule . . . . .	275
6. Effects on Megakaryocytopoiesis . . . . .	277
a) In Vitro Effects . . . . .	277
b) In Vivo Effects . . . . .	279
7. Effects on Thrombocytopoiesis . . . . .	281
a) Platelet Counts . . . . .	281
b) Platelet Sizes . . . . .	282
c) Isotope Incorporation . . . . .	282
D. Other Factors Affecting Thrombocytopoiesis . . . . .	283
I. Effects of Hypoxia . . . . .	283
II. Effects of Erythropoietin and Other Growth Factors . . . . .	284
E. Clinical Aspects of Thrombopoietin . . . . .	286
F. Future of Thrombopoietin . . . . .	288
References . . . . .	289

## CHAPTER 9

**Arachidonic Acid Metabolism Platelets and Thromboembolic Disease**

D.M. KERINS and G.A. FITZGERALD. With 6 Figures . . . . .	299
A. Arachidonic Acid Metabolism . . . . .	299
I. Introduction . . . . .	299
II. The Cyclooxygenase Pathway . . . . .	299
III. Shunting of Endoperoxides . . . . .	304
IV. The Lipoxygenase Pathway . . . . .	305
V. The Epoxygenase Pathway . . . . .	307
VI. Pharmacology of Antiplatelet Agents . . . . .	309
B. Thromboembolic Disease . . . . .	311
I. Introduction . . . . .	311
II. Unstable Angina . . . . .	311
III. Acute Myocardial Infarction . . . . .	315
1. Secondary Prevention . . . . .	315
2. Coronary Thrombolysis . . . . .	320
3. Primary Prevention . . . . .	321
IV. Coronary Bypass Grafts . . . . .	324
V. Peripheral Arterial Grafts . . . . .	327
VI. Cerebrovascular Disease . . . . .	329
VII. Prosthetic Valves . . . . .	332
VIII. Coronary Angioplasty . . . . .	334
C. Concluding Comments . . . . .	338
References . . . . .	339

## CHAPTER 10

**Chemical Agents That Inhibit Platelet Aggregation**

J.B. SMITH and D.C.B. MILLS. With 4 Figures . . . . .	353
A. Introduction . . . . .	353
B. Platelet Physiology . . . . .	354
C. Platelet Structure . . . . .	354
D. Platelet Involvement in Thrombosis . . . . .	355
E. Platelet Responses . . . . .	355
I. Shape Change . . . . .	356
II. Adhesion . . . . .	357
III. Aggregation . . . . .	358
F. Inhibition of Platelet Aggregation . . . . .	358
I. Cyclic AMP . . . . .	358
II. Cyclic GMP . . . . .	361
III. Receptor Antagonism . . . . .	362
1. Catecholamines . . . . .	362
2. Serotonin . . . . .	363

3. ADP . . . . .	364
4. Prostaglandin Endoperoxides and Thromboxane A <sub>2</sub> . . . . .	364
5. Vasopressin . . . . .	365
6. Platelet Activating Factor . . . . .	365
7. Thrombin . . . . .	366
8. Collagen . . . . .	366
IV. Arachidonate Metabolism . . . . .	367
1. Source of Arachidonate . . . . .	367
2. Inhibitors of Phospholipase A <sub>2</sub> . . . . .	367
3. Inhibitors of Cyclooxygenase . . . . .	367
4. Thromboxane Synthase Inhibitors . . . . .	368
5. Inhibitory Prostaglandins . . . . .	369
V. Experimental Drugs with Unknown Actions . . . . .	370
G. Conclusions . . . . .	371
References . . . . .	371

## CHAPTER 11

### Anticoagulants, Antithrombotic and Thrombolytic Agents

M. DUGDALE. With 6 Figures . . . . .	377
A. Anticoagulants . . . . .	380
I. Heparin . . . . .	380
1. Clinical Applications . . . . .	382
2. Prophylactic (Low-Dose) Heparin . . . . .	384
3. Complications . . . . .	385
II. New Therapies . . . . .	388
1. Heparin plus Dihydroergotamine . . . . .	388
2. Low Molecular Weight Heparins . . . . .	388
III. Oral Anticoagulants . . . . .	392
1. Complications . . . . .	397
B. Thrombolytic Therapy . . . . .	399
I. Streptokinase . . . . .	401
II. Urokinase (and Single Chain Urokinase) . . . . .	404
III. Tissue Plasminogen Activator . . . . .	405
IV. Acyl Plasminogen Streptokinase Activation Complex . . . . .	406
V. Novel Approaches . . . . .	407
1. Defibrotide and Brinase . . . . .	407
VI. Side Effects and Complications . . . . .	408
VII. Clinical Considerations . . . . .	411
1. Acute Myocardial Infarction (Coronary Thrombosis) . . . . .	412
2. Arterial Occlusion . . . . .	420
3. Pulmonary Embolism . . . . .	422
4. Deep Venous Thrombosis . . . . .	424

Contents	XV
C. Antithrombotic Therapy . . . . .	426
I. Dextrans . . . . .	426
II. Physical Methods . . . . .	427
III. Refibrinogenating Agents . . . . .	428
References . . . . .	429

## CHAPTER 12

### **Granulocyte-Macrophage Growth Factors**

P.J. QUESENBERRY. With 2 Figures . . . . .	449
A. Introduction . . . . .	449
B. Historical Background . . . . .	449
C. Growth Factors . . . . .	451
I. Colony Stimulating Factor-1 . . . . .	453
II. Granulocyte-Macrophage-Colony Stimulating Factor . . . . .	456
III. Granulocyte-Colony Stimulating Factor . . . . .	459
IV. Interleukin-3 . . . . .	462
D. Other Interleukins . . . . .	465
I. Interleukin-1 . . . . .	466
II. Interleukin-2 . . . . .	467
III. Interleukin-4 . . . . .	468
IV. Interleukin-5 . . . . .	469
V. Interleukin-6 . . . . .	469
VI. Interleukin-7 . . . . .	470
E. Inhibitors . . . . .	470
F. Cellular Production and Networking . . . . .	471
G. Microenvironment . . . . .	472
H. Conclusions . . . . .	474
References . . . . .	474

## CHAPTER 13

### **Chemical Agents Which Suppress Myelopoiesis: Agranulocytosis and Leukemia**

R.A. JOYCE. With 3 Figures . . . . .	493
A. Introduction . . . . .	493
B. Normal Marrow Cell Kinetics . . . . .	494
C. Pathophysiologic Mechanisms for Drug-Induced Neutropenia . . . . .	498
D. Neutropenia Associated with Cytotoxic Chemotherapeutic Agents . . . . .	500
E. Drug-Induced Myeloid Suppression . . . . .	503
I. Ethanol . . . . .	504
II. Phenothiazines . . . . .	505
III. Anticonvulsants . . . . .	505

IV. Antiinflammatory Agents . . . . .	506
V. Antiviral Agents . . . . .	506
VI. H <sub>2</sub> Receptor Antagonists . . . . .	507
VII. Miscellaneous Agents . . . . .	508
F. Idiosyncratic Neutropenias . . . . .	508
I. Analgesics . . . . .	508
II. Antibiotics . . . . .	509
III. Cardiovascular Drugs and Diuretics . . . . .	510
IV. Thyrostatic Agents . . . . .	511
V. Sulfonamides . . . . .	511
G. Pseudoneutropenia . . . . .	511
I. Complement Activation . . . . .	512
II. Expression of Membrane Adhesion Molecules . . . . .	512
H. Secondary Leukemia . . . . .	512
J. Conclusions . . . . .	514
References . . . . .	514

## CHAPTER 14

### Drugs Useful in the Chemotherapy of the Acute Leukemias

R.L. CAPIZZI and K. AGRAWAL. With 6 Figures . . . . .	523
A. Introduction . . . . .	523
B. Antimetabolites . . . . .	526
I. Cytosine Arabinoside (1-β-D-arabinofuranosylcytosine) . . . . .	527
II. 6-Mercaptopurine and 6-Thioguanine . . . . .	534
III. Methotrexate . . . . .	538
C. Drugs that Intercalate in DNA . . . . .	540
I. Daunorubicin and Doxorubicin . . . . .	540
II. Amsacrine . . . . .	542
D. Podophyllotoxin Derivatives . . . . .	542
I. Etoposide and Teniposide . . . . .	542
E. Vinca Alkaloids . . . . .	543
I. Vincristine . . . . .	543
F. Alkylating/DNA Binding Agents . . . . .	544
I. Cyclophosphamide . . . . .	544
II. Carboplatin . . . . .	545
G. Adrenal Glucocorticoids . . . . .	547
I. Prednisone . . . . .	547
H. Enzymes . . . . .	548
I. Asparaginase . . . . .	548
J. Multidrug Resistance . . . . .	553
References . . . . .	554
<b>Subject Index . . . . .</b>	<b>565</b>